<DOC>
	<DOCNO>NCT00128596</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well arsenic trioxide work treat patient metastatic liver cancer remove surgery .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Metastatic Liver Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy arsenic trioxide patient unresectable metastatic hepatocellular carcinoma . - Determine safety tolerability drug patient . OUTLINE : Patients receive load dose arsenic trioxide IV 1-2 hour daily day 1-5* week 1 twice weekly week 2-8 . Courses repeat every 8 week absence disease progression unacceptable toxicity . NOTE : *The 5-day loading dose administer course 1 . After completion study treatment , patient follow 30 day periodically 2 year . PROJECTED ACCRUAL : A total 15-25 patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatocellular carcinoma Unresectable metastatic disease Ascites allow provide minimal PATIENT CHARACTERISTICS : Age Over 18 Performance status 02 Life expectancy Not specify Hematopoietic WBC &gt; 2,500/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 75,000/mm^3 Hepatic Bilirubin &lt; 2.5 mg/dL AST &lt; 2.5 time upper limit normal Renal Not specify Cardiovascular QTc interval ≤ 460 msec AND potassium magnesium normal Other Not pregnant nursing Negative pregnancy test Fertile female patient must use effective doublemethod contraception ≥ 4 week , , ≥ 4 week completion study treatment ( ≥ 4 week completion study treatment male patient ) No blood , ovum , sperm donation study treatment Potassium &gt; 4.0 mEq/dL Magnesium &gt; 1.8 mg/dL PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic therapy Chemotherapy More 4 week since prior concurrent chemotherapy Endocrine therapy Not specify Radiotherapy More 4 week since prior concurrent radiotherapy Surgery Not specify Other No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>